Cognivue develops FDA-cleared digital cognitive assessment devices for earlier detection of potential cognitive impairment in healthcare settings. Conceived and developed in part by President and CEO Paul W. Estes beginning in 2009, its adaptive-psychophysics technology customizes self-administered testing to each patient’s visual and motor capabilities while collecting more than 130,000 data points. Based in Victor, New York, Cognivue supports clinical use and research through products including the five-minute Thrive screen and the more comprehensive Clarity assessment.
FDA-cleared technology
FDACLEARANCE
Quality certification
BrainScope Company, IncFounded in 2006, BrainScope develops medical neurotechnology that converts brain electrical activity (EEG) into objective, point-of-care assessments for brain health. Its FDA-cleared system was the first AI/machine-learning medical device cleared in neurology and is used to assess head injuries for the likelihood of brain bleeds and concussion without radiation. The company is now extending its EEG-based platform into digital biomarkers for conditions including stroke and cognitive decline.ROCKVILLE, MD
Cognitive Signals INCCognitive Signals is a technology company developing MINDTRACE to measure human cognitive states in real time. Its passive, non-invasive system uses brain responses to help organizations understand engagement and learning without relying on questions or physical input.
Neurosteer IncFounded in 2015 by Tel Aviv University professor Nathan Intrator, Neurosteer develops a wearable, medical-grade brain-activity interpretation platform built around a pocket-sized, single-channel EEG monitor. Its wireless forehead sensor and cloud-based analysis provide real-time brain metrics for clinical assessment, continuous monitoring and research, and the device has FDA Class II clearance. Neurosteer’s teams work across New York, California and Israel, drawing on expertise in neuroscience and signal processing.NEW YORK, NY
Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY